Cyclosporine A and amphiphilic hyaluronic acid derivative composition and preparation method thereof

A technology of hyaluronic acid and cyclosporine, which is applied in the field of medicine, can solve the problems of low bioavailability, and achieve the effects of simple production process, high drug loading, and good biocompatibility

Inactive Publication Date: 2013-07-10
CHINA PHARM UNIV
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The composition can overcome the shortcomings of the existing cyclosporine A preparations such as low bioavailability, severe toxic and side effects, etc., and can prepare a drug with high drug loading, low toxic and side effects, good stability, good biocompatibility, and convenient storage and transportation. cyclosporine A ophthalmic preparation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cyclosporine A and amphiphilic hyaluronic acid derivative composition and preparation method thereof
  • Cyclosporine A and amphiphilic hyaluronic acid derivative composition and preparation method thereof
  • Cyclosporine A and amphiphilic hyaluronic acid derivative composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Preparation of Amphiphilic Hyaluronic Acid Derivatives (HA-g-PNIPAAm)

[0029] a. Preparation of hyaluronic acid intermediate AHA

[0030] Accurately weigh 100 mg of hyaluronic acid HA, and add 200 ml of distilled water to fully dissolve the HA. Then add 1.736 g of adipic acid dihydrazide ADH to the above solution, mix thoroughly and stir for 20 minutes, and adjust the pH to 4.8 with 0.1 mol HCl solution. Add 20ml of ethanol and stir for 30 minutes. Add 0.191 g of EDC·HCl, adjust the pH value with 0.1 mol HCl solution, and keep the reaction pH at 4.8. After 2 hours, the reaction ends, and adjust the pH value to 7.0 with 0.1 mol NaOH solution. The reaction solution was transferred into a pre-washed dialysis bag (molecular weight cut off 7KDa). 0.1mol NaCl was used as the dialysate. After 24 hours of dialysis, deionized water was used as the dialysate. After 24 hours of dialysis, it was centrifuged for 15 minutes at 3500 rpm. The supernatant was taken, passe...

Embodiment 2

[0035] Example 2 Preparation of cyclosporine A and amphiphilic hyaluronic acid derivatives (HA-g-PNIPAAm)

[0036] The drug was loaded by dialysis, and the drug was cyclosporine CsA. Weigh 20mg of HA-g-PNIPAAm, add 2ml of double distilled water, and fully swell at room temperature for 30min. Dissolve 6 mg of cyclosporine A in a pharmaceutically acceptable organic solvent and add dropwise to the above solution, and ultrasonically pass through the probe for 30 minutes, and the drug and HA-g-PNIPAAm form a nanogel. Transfer the above nanogel into a pre-washed dialysis bag (molecular weight cut-off 3500Da), dialyze with deionized water for 1 day, freeze-dry for 36 hours after pre-freezing for 24 hours, and obtain cyclosporine A and amphiphilic hyaluronic acid derivatives Composition freeze-dried product. In the above preparation method, acceptable organic solvents for dissolving cyclosporine A include methanol, ethanol, chloroform, ethyl acetate, acetone, ether, preferably ethan...

Embodiment 3

[0037] Example 3 Characterization of Substitution Degree of Amphiphilic Hyaluronic Acid Derivatives

[0038] Dissolve 0.10g of hyaluronic acid intermediate AHA in 40ml of water; respectively take 0.10g, 0.20g, and 0.30g of poly-N isopropylacrylamide PNIPAAm-COOH with carboxyl groups at the end and dissolve them in deionized water, and then add 0.10g to the solution. gEDC·HCl, incubated at 4°C for 48h. The two solutions were thoroughly mixed, the pH was adjusted to 5.6, and the mixture was stirred at room temperature for 24 h. The reaction solution was transferred into a pre-washed dialysis bag (molecular weight cut-off 3500Da), dialyzed with deionized water for 3 days, pre-frozen for 24 hours and then freeze-dried for 36 hours to obtain the frozen amphiphilic hyaluronic acid derivative HA-g-PNIPAAm. Dried product, refrigerated at -4°C for later use. Calculate the degree of substitution (DS) of the sample with formula (1), W is the mass, and MW is the molecular weight. The re...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines and discloses a cyclosporine A and amphiphilic hyaluronic acid derivative composition and a preparation method thereof. The composition is prepared from cyclosporine A and the amphiphilic hyaluronic acid derivative. The composition has the characteristics of high medicine loading capacity, good stability and good biocompatibility and can overcome such defects of the ophthalmic cyclosporine preparations as lower bioavailability and toxic and side effects. The preparation method is simple and is convenient to use.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a composition of cyclosporin A and amphiphilic hyaluronic acid derivatives and a preparation method thereof. Background technique [0002] Cyclosporin is cyclosporine (Cyclosporine), and clinically commonly used cyclosporin A (Cyclosporin A, CsA) is a cyclic polypeptide compound composed of 11 amino acids. It is a third-generation immunosuppressant and is currently used clinically. The most effective drug against organ transplant rejection. However, systemic application of cyclosporine preparations has low bioavailability and can easily lead to decreased systemic immunity, and can also cause serious side effects, such as hypertension, liver and kidney toxicity, central nervous system toxicity, lymphoma, etc., so local application methods are used to directly target the lesion Effect, not only reduce the dosage of drugs but also reduce the side effects. [0003] Eye application o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/13A61K47/48A61P37/06A61P27/02C08B37/08A61K47/36
Inventor 周建平姚静武毅君
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap